OS Therapies (OSTX) Liabilities and Shareholders Equity (2023 - 2026)
OS Therapies' (OSTX) quarterly Liabilities and Shareholders Equity came in at $7.3 million in Q1 2026, up 71.75% YoY from $4.2 million in Q1 2025, and up 6.72% on a QoQ basis from $6.8 million in Q4 2025.
OS Therapies (OSTX) Liabilities and Shareholders Equity (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $7.3 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 71.75% year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.4 million (up 154.82% YoY) and the FY2025 annual result came in at $6.8 million, up 23.48% from the prior year.
- Liabilities and Shareholders Equity improved to $7.3 million in Q1 2026, from $6.8 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $10.3 million in Q2 2025 to a low of $798082.0 in Q4 2023.
- A 4-year average of $4.8 million and a median of $4.9 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- The widest YoY moves for Liabilities and Shareholders Equity: up 668.17% in 2025, down 23.48% in 2025.
- Tracing OSTX's Liabilities and Shareholders Equity over 4 years: stood at $798082.0 in 2023, then surged by 594.01% to $5.5 million in 2024, then grew by 23.48% to $6.8 million in 2025, then grew by 6.72% to $7.3 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $7.3 million (Q1 2026), $6.8 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | OS Therapies | 19.46 Mn | 19.46 Mn | - | 9.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.30 Mn |
| Dec 31, 2025 | 6.84 Mn |
| Sep 30, 2025 | 8.95 Mn |
| Jun 30, 2025 | 10.31 Mn |
| Mar 31, 2025 | 4.25 Mn |
| Dec 31, 2024 | 5.54 Mn |
| Sep 30, 2024 | 1.98 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Mar 31, 2024 | 1.05 Mn |
| Dec 31, 2023 | 798,082.00 |